DMU-212

CAS No. 134029-62-2

DMU-212( —— )

Catalog No. M28078 CAS No. 134029-62-2

DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the promotion of apoptosis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 51 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 76 In Stock
25MG 155 In Stock
50MG 268 In Stock
100MG 398 In Stock
200MG Get Quote In Stock
500MG 901 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DMU-212
  • Note
    Research use only, not for human use.
  • Brief Description
    DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the promotion of apoptosis.
  • Description
    DMU-212, a methylated form of Resveratrol, shows antimitotic, antiproliferative, and antioxidant activities. DMU-212 induces mitotic arrest through the activation of ERK1/2 protein and the promotion of apoptosis.(In Vitro):DMU-212 (0.3125-40 μM) inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC50=0.5 μM, 0.5 μM, 1.25 μM, and 1.25 μM for A375, Bro, MeWo, and M5 human melanoma cells, respectively.).(In Vivo):In SCID female mice, DMU-212 (50 mg/kg; i.g.) inhibited tumor growth and lowered tumor burden.
  • In Vitro
    Cell Proliferation Assay Cell Line:A375 cells, MeWo cells, M5 cells, Bro cells Concentration:0.3125 μM, 0,625 μM, 1.25 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM Incubation Time:96 hours Result:Inhibited the cellular proliferation of human melanoma cells at submicromolar or micromolar concentrations (IC50=0.5 μM for A375 and Bro and IC50= 1.25 μM for MeWo and M5 cells).Cell Cycle Analysis Cell Line:A375 cells Concentration:20 μM, 30 μM, 50 μM Incubation Time:24 hoursResult:Caused a marked increase in the levels of p21, p53 and cyclin B1 proteins with a concomitant decrease in the levels of cyclin A2.Western Blot Analysis Cell Line:A375 cells Concentration:20 μM, 30 μM, 50 μM Incubation Time:24 hours Result:Significant upregulated Bax, caspase 3 and caspase 9 protein levels, while decreased the levels of the anti-apoptotic protein Bcl-2.Apoptosis Analysis Cell Line:A375 cells Concentration:10 μM, 20 μM Incubation Time:24 hours, 36 hoursResult:Induced apoptosis.
  • In Vivo
    Animal Model:6-weeks-old SCID female mice (20-24 g), with ovarian cancer xenografts Dosage:50 mg/kg Administration:Oral gavage, three times a week, for 14 days Result:Lowered tumor burden.
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Tubulin polymerization
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    134029-62-2
  • Formula Weight
    300.35
  • Molecular Formula
    C18H20O4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 20 mg/mL (66.59 mM)
  • SMILES
    COC1=CC=C(/C=C/C2=CC(OC)=C(OC)C(OC)=C2)C=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Schneider Y, et al. Resveratrol analog (Z)-3,5,4'-trimethoxystilbene is a potent anti-mitotic drug inhibiting tubulin polymerization. Int J Cancer. 2003 Nov 1;107(2):189-96.
molnova catalog
related products
  • PDK4-IN-1 hydrochlor...

    PDK4-IN-1 hydrochloride is an anthraquinone derivative and a potent and orally active inhibitor of pyruvate dehydrogenase kinase 4 (PDK4, IC50 value = 84 nM).

  • Juglanin

    Juglanin is a JNK activator. Juglanin with inflammation and anti-tumor activities. It can induce apoptosis and autophagy on human breast cancer cells.

  • BTM-3528

    BTM-3528 is an activator of the mitochondrial protease OMA1 with anticancer activity.BTM-3528 activates the ISR via the mitochondrial protease OMA1, inducing OMA1-dependent cleavage of DELE1 and OPA1 and mitochondrial fragmentation.